Tagged with biosimilars,

Belgium Miranda Heining, general manager of Fresenius Kabi for Belgium and the Netherlands, speaks about the career path that led her to join the pharma industry and lead the affiliate, her experience managing two countries simultaneously, and the potential pitfalls in navigating Belgium’s market access landscape.   The complexity of the…

Czech Republic As one of the few pharma companies in the Czech Republic to offer products across the whole healthcare spectrum, including prescription drugs, generics, over-the-counter (OTC) treatments, and food supplements, the 125-year-old German firm STADA has established a strong Czech affiliate in recent times.   The beauty of STADA is that…

China The Chinese healthcare market has transformed dramatically in the past few years. There have been many reforms centred around the country’s vision of becoming a healthcare technology powerhouse in the next couple of decades and ‘innovation’ has become a buzzword touted by both foreign and local players alike. But in…

Europe Isabell Remus, chair of the Biosimilar Medicines Group at Medicines for Europe outlines the issues that need to be addressed to keep driving biosimilar uptake in Europe.   Since the first treatment was approved in 2006, Europe has been at the vanguard of the biosimilar medicines sector, approving more treatments…

USA The AAM’s Chip Davis gives an account of his agenda for 2020, how the association is driving policy in a complex healthcare environment of multiple public and private actors and offers insight as to why there is great room for improvement in the uptake of biosimilar drugs.   The question,…

India Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia and New Zealand markets.   We see ourselves as a company that has great capabilities and is investing big time…

Hungary Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company’s performance, its exciting new collaboration with Allergan in the US market, and the landmark launch of Gedeon’s first company-developed biosimilar in Japan.   Our advancement in biotechnology has been a key development for Gedeon Richter this year…

Hungary István Hodász, CEO of Egis Pharmaceuticals PLC, introduces the longstanding history of the company and its positioning as a leading manufacturer of value-added generics with a strong presence in the CEE market. Hodász goes on to highlight the company’s recent milestones, including manufacturing investments, portfolio acquisitions, new therapeutic area strategies,…

Hungary Jānis Meikšāns, newly appointed general manager of Teva Hungary, speaks about his first few months in the country. Meikšāns goes on to elaborate on Hungary’s key positioning as a strategic affiliate for Teva with strong R&D and manufacturing operations. Additionally, he highlights Teva’s longstanding commitment to the country not only…

Hungary Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in biologics R&D.   Biosimilars in Europe Over the past decade, over 80 biologic molecules have been launched worldwide. By 2020…

USA The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save billions of dollars and increase patient access to lifesaving medications.     In a nutshell: competition brings prices down across the board Biologic drugs…

Generics Christoph Stoller, general manager for Austria and Germany at Teva was recently elected president of Medicines for Europe, the continent-wide association for the generics and biosimilars industries. Stoller plans to focus his efforts on improving access to generics and biosimilars in Europe, as well as tackling the damaging issue of…